文献速递青光眼

全身用药与青光眼进展及疑似转归的关联:Groningen纵向青光眼研究

Association of Systemic Medication Exposure With Glaucoma Progression and Glaucoma Suspect Conversion in the Groningen Longitudinal Glaucoma Study.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

该回顾性队列研究分析了Groningen纵向青光眼研究中原发性开角型青光眼(POAG)患者和疑似者的记录,评估他汀类、五类降压药和质子泵抑制剂与POAG进展及疑似者转归的关联。结果显示,未发现全身用药与POAG进展总体相关,但血管紧张素II受体阻滞剂(ARBs)在老年患者中延缓进展;血管紧张素转换酶抑制剂(ACEIs)和ARBs与疑似者转归风险降低显著相关。

要点

  • 未发现他汀类、降压药或质子泵抑制剂与POAG进展总体相关。
  • ARBs在老年患者中可能延缓视野进展(b=0.014,P=0.0001)。
  • ACEIs和ARBs与POAG疑似者转归风险降低显著相关。

核心结论

  • 未发现全身用药与POAG视野进展总体相关,但ARBs在老年患者中延缓进展。
  • ACEIs和ARBs与POAG疑似者转归风险降低相关,其病理生理机制尚待阐明。

研究设计与样本

  • 回顾性队列研究,纳入Groningen纵向青光眼研究的POAG患者和疑似者。
  • 以平均偏差(MD)进展速率量化患者视野恶化,疑似者转归定义为至少一眼连续两次视野检查异常(青光眼半视野测试超出正常限)。
  • 采用分位数回归和逻辑回归分析,控制年龄、性别、体质指数、治疗前眼压、角膜厚度和基线MD。

主要发现

  • 在最终眼压/治疗调整或未调整模型中,无全身用药与POAG进展相关。
  • ARBs在老年患者中显示延缓进展(b=0.014,P=0.0001)。
  • ACEIs与疑似者转归降低显著相关(调整后OR 0.23,95%CI 0.07-0.79,P=0.012;未调整OR 0.24,95%CI 0.07-0.78,P=0.021)。
  • ARBs与疑似者转归降低显著相关(调整后OR 0.12,95%CI 0.01-0.98,P=0.014;未调整OR 0.11,95%CI 0.01-0.87,P=0.005)。

关键数值与推荐

  • 疑似者转归定义:至少一眼连续两次视野检查异常(青光眼半视野测试超出正常限)。
  • ARBs延缓老年患者进展的回归系数b=0.014,P=0.0001。
  • ACEIs与转归降低的调整后OR 0.23(95%CI 0.07-0.79,P=0.012),未调整OR 0.24(95%CI 0.07-0.78,P=0.021)。
  • ARBs与转归降低的调整后OR 0.12(95%CI 0.01-0.98,P=0.014),未调整OR 0.11(95%CI 0.01-0.87,P=0.005)。

临床怎么用

  • 对于老年POAG患者,使用ARBs可能有助于延缓视野进展。
  • ACEIs或ARBs的使用可能与POAG疑似者转归风险降低相关,但需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the association of statins, five classes of antihypertensive medications, and proton pump inhibitors with (1) primary open-angle glaucoma (POAG) progression and (2) conversion of POAG suspects to POAG. METHODS: We retrospectively investigated the records of a cohort with POAG cases and suspects from the Groningen Longitudinal Glaucoma Study. To quantify visual field (VF) deterioration in cases, we used the rate of progression of the mean deviation (MD). Suspects were considered to have converted at the time point after which two consecutive VF tests for at least one eye were abnormal (glaucoma hemifield test outside normal limits). Progression and conversion were analyzed with quantile and logistic regression, respectively, with the systemic medications as predictors, controlling for age, sex, body mass index, pretreatment IOP, corneal thickness, and baseline MD. The multivariable models were built with and without IOP intervention. RESULTS: No systemic medications were associated with POAG progression in the final IOP/treatment-adjusted or unadjusted model. However, angiotensin II receptor blockers (ARBs) appeared to slow progression in older patients (b = 0.014, P = 0.0001). Angiotensin-converting enzyme inhibitors (ACEIs) were significantly associated with a decrease in POAG suspect conversion in both the IOP/treatment-adjusted and -unadjusted model (odds ratio [OR] 0.23, 95% confidence interval [CI] 0.07-0.79, P = 0.012; OR=0.24, 95% CI 0.07-0.78, P = 0.021, respectively), as were ARBs (OR 0.12, 95% CI 0.01-0.98, P = 0.014; OR 0.11, 95% CI 0.01-0.87, P = 0.005, respectively). CONCLUSIONS: No overall association of VF progression with systemic medication was found; ARBs delayed progression in older patients. ACEIs and ARBs were associated with lower risk of suspect conversion. The pathophysiology of this relationship is to be disentangled.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Pappelis K, Loiselle AR, Visser S, et al. Association of Systemic Medication Exposure With Glaucoma Progression and Glaucoma Suspect Conversion in the Groningen Longitudinal Glaucoma Study. Invest Ophthalmol Vis Sci. 2019. PMID: 31675072. doi:10.1167/iovs.19-27984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。